Five-year real world outcomes of GeoForm ring implantation in patients with ischemic mitral regurgitation  by Timek, Tomasz A. et al.
Timek et al Acquired Cardiovascular DiseaseFive-year real world outcomes of GeoForm ring implantation
in patients with ischemic mitral regurgitationTomasz A. Timek, MD,a Robert L. Hooker, MD,a Robin Collingwood, MD,b Alan T. Davis, PhD,c
Craig T. Alguire, MD,a Charles L. Willekes, MD,a Edward T. Murphy, MD,a John C. Heiser, MD,a and

















DBackground: Reductive ring annuloplasty represents the current standard surgical therapy for ischemic mitral
regurgitation (IMR); however, the clinical results have been suboptimal. Etiology-specific prostheses such as the
GeoForm annuloplasty ring have been designed to better address the annular and subvalvular perturbations asso-
ciated with IMR. However, clinical experience is limited, and mid-term results are lacking.
Methods:We reviewed the clinical outcomes of 86 patients who had undergone implantation of a GeoForm ring
at our center from 2005 to 2011. Perioperative mortality and clinical parameters were derived from The Society
of Thoracic Surgeons database. Follow-up survival was assessed using the Social Security Death Index. Surviv-
ing patients were interviewed by telephone for valve-specific follow-up data and to complete the Medical Out-
comes Study, short-form, 36-item, quality-of-life questionnaire.
Results: The mean grade of IMR preoperatively was 3.1  0.8 (range, 1-4þ), 0.2  0.4 in the immediate post-
operative period, and 0.7  0.7 at the last mean follow-up point of 41 months; only 2 patients developed
2þ IMR during the follow-up period, for a 5-year freedom from recurrent 2þ IMR of 86%. The mean left
ventricular end-diastolic and end-systolic diameters decreased from before to after surgery from 6.0  0.0
cm to 5.3  09 cm and 5.0  0.9 cm to 4.3  1.1 cm, respectively (P<.001). Perioperative mortality was
5.8% (5 of 86), and 1-, 3-, and 5-year survival was 87%, 81%, and 75%, respectively. At the last follow-up
point, 80% of patients were in New York Heart Association class I and II, and their quality of life was equal
to, or better than, age-matched controls from the general population.
Conclusions: Implantation of the GeoForm ring offers very good control of IMR, with low rate of recurrent IMR
at mid-term follow-up. The use of this prosthesis was associated with good perioperative mortality, mid-term
survival, and quality of life. (J Thorac Cardiovasc Surg 2014;148:1951-6)Ischemic mitral regurgitation (IMR) continues to be a chal-
lenging clinical problem for surgeons and cardiologists
alike. The etiology of IMR has yet to be clearly elucidated,
although recent clinical1 and experimental2 data have
significantly contributed to our understanding of the annular
and subvalvular perturbations that contribute to its genesis.
The current standard clinical repair of IMR has been
centered around annular reduction using a complete under-
size annuloplasty ring. However, the need for subvalvular
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The Journal of Thoracic and Carbeen increasingly recognized.3,4 Annular septal-lateral
(SL) reduction is paramount for the efficacy of annuloplasty
rings5 and, in experimental models, has also been shown to
simultaneously alter ventricular geometry.6 This increasing
body of clinical and experimental data have led to the devel-
opment of etiology-specific annuloplasty rings to treat IMR
by addressing annular and subvalvular geometric perturba-
tions with a customized annular prosthesis. The GeoForm
annuloplasty ring (Edwards Lifesciences, Irvine, Calif) of-
fers significant annular septal reduction while maintaining
the annular orifice area and has been specifically developed
to treat IMR.7 The 3-dimensional shape of the prosthesis is
designed to enhance leaflet coaptation and simultaneously
alter the subvalvular geometry. However, the clinical effi-
cacy of this novel annuloplasty ring and the mid-term re-
sults have not yet been firmly established. We reviewed
the clinical results of all patients with IMR who had been
implanted with the GeoForm ring at our center during a
7-year period.METHODS
The institutional review board approved our study, which was in full
compliance with its policies and procedures. We performed a retrospective
review of the data from all patients entered in our local Society of Thoracicdiovascular Surgery c Volume 148, Number 5 1951
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IMR ¼ ischemic mitral regurgitation
LV ¼ left ventricular
NYHA ¼ New York Heart Association
SF-36 ¼ Medical Outcomes Study 36-item
short-form health survey
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DSurgeons database from January 2005 to January 2011 who had undergone
implantation of the GeoForm annuloplasty ring for treatment of IMR. The
general indication for clinical use of the GeoForm prosthesis in our practice
was patients with significant (at least moderate) functional or IMR with a
low ejection fraction (<35%) and a significantly dilated mitral annulus and
left ventricular (LV) cavity. All patients were included, regardless of the
preoperative degree of mitral insufficiency and additional or previous car-
diac procedures. All surgeries were performed at a single center within a
university-affiliated cardiac surgical practice. The operative procedure
was performed according to surgeon preference but predominantly
included clamping of the internal mammary artery in cases with previous
patent coronary grafts, mild systemic hypothermia, and both anterograde
and retrograde cold blood cardioplegia delivery. The heart was typically ar-
rested with cold anterograde blood cardioplegia, and, subsequently, cold
retrograde blood cardioplegia was redelivered every 15 to 20 minutes
throughout the procedure. A septal temperature probe was used, and a tem-
perature<10C was achieved with each dose. Before crossclamp removal,
500 mL of warm retrograde cardioplegia was delivered, followed by 5 mi-
nutes of warm blood retrograde perfusion as a ‘‘hot shot.’’ The implanted
rings were sized using the clinical criteria of intertrigonal distance and sub-
sequent downsizing of 1 to 2 sizes, depending on the degree of LV dysfunc-
tion, patient size, and LV chamber remodeling. All patients received either
a 26- or 28-mm ring. The ring was implanted using multiple (15-20) 2-0
Ethibond sutures to better distribute the tension and reduce the risk of pros-
thesis dehiscence. The anterior portion of the ring was tied down first. Sub-
sequently, alternating sutures were tied, starting from each trigone and
working toward the center of the posterior annulus. The midposterior
‘‘hump’’ of the ring was tied last to minimize the chance of prosthesis
dehiscence from high suture tension. The perioperative mortality and
30-day events were queried directly from The Society of Thoracic Sur-
geons database. Follow-up regarding late mortality was conducted using
the Social Security Death Index and was 100% complete. For all deceased
patients, death certificates were obtained to determine the cause of death.
The EuroSCORE II score was calculated using the available on-line
calculator and preoperative risk factors. The pre- and postoperative echo-
cardiograms (294 total) were reviewed by a single experienced echo-
cardiographer (C.T.A.) to assess the degree of MR and ventricular function
and geometry preoperatively, in the early postoperative period (intraoper-
ative or within 6 months), and at the last available follow-up visit beyond
6 months. The degree of MR was determined by visual inspection of the
extent of the regurgitant jet traversing the left atrium, reversal of flow in
the pulmonary veins, and measurements of the vena contracta width. MR
was graded using these standard clinical criteria on a 0 to 4þ scale. Surviv-
ing patients were interviewed by telephone to complete the Medical Out-
comes Study 36-item short-form health survey (SF-36) questionnaire and
valve-related morbidity questions. The SF-36 evaluates 8 dimensions of
health: physical functioning, role limitations due to physical problems,
bodily pain, general health perception, vitality, social function, role limita-
tions due to emotional problems, and mental health. In addition, the SF-36
provides summary scales for overall physical and mental health. Valve-
related morbidity was reported according to established guidelines.8 The
preoperative patient characteristics and postoperative morbidity were
defined using The Society of Thoracic Surgeons criteria. All patient data1952 The Journal of Thoracic and Cardiovascular Surare reported as the group mean  standard deviation. The Kaplan-Meier
method was used to determine actuarial survival.RESULTS
A total of 86 patients underwent implantation of the Geo-
Form annuloplasty ring. The preoperative clinical charac-
teristics are listed in Table 1. Most patients had 3þ MR,
and the mean MR grade was 3.1  0.8 (range, 1-4þ).
Most regurgitant jets were centrally oriented, and the
mean preoperative annular SL dimension was 3.9  0.5
cm. The operative data and associated cardiac procedures
are summarized in Table 2. The cardiopulmonary bypass
time and aortic crossclamp time were prolonged, reflecting
complex operative procedures, with a 20% rate of reopera-
tive surgery. However, most of the prolonged operative time
was driven by an aggressive revascularization strategy,
because 78% of patients had undergone concurrent coro-
nary artery bypass grafting, and the mean number of grafts
was 3.5  1.4. The 30-day mortality was 5.8% (5 of 86),
and the rate of renal failure and re-exploration for bleeding
was 11.1% (10 of 86) and 2.3% (2 of 86), respectively. No
perioperative neurologic events occurred. The mean post-
operative ventilator time was 54 127 hours, and the inten-
sive care unit stay was 125  162 hours.
At a mean follow-up period of 50 17 months postoper-
atively, 49 of the 65 surviving patients (75%) were inter-
viewed by telephone to assess valve-related morbidity and
complete the SF-36 questionnaire. Of the 49 patients, 18
(37%) were in New York Heart Association (NYHA) class
1, 21 (43%) were in NYHA class II, and 10 (20%) were in
either NYHA class III or IV. During the follow-up interval,
4 (8%) of the 49 patients developed bleeding complica-
tions, 3 (6%) had neurologic events, 1 (2%) had endocardi-
tis, 29 (60%) were receiving anticoagulant therapy, and 27
(55%) had permanent pacemakers. The high permanent
pacemaker rate was reflective of an aggressive strategy us-
ing biventricular pacing for potential improvement of LV
function, because 43% of the study patients had received
either a biventricular pacer or a LV pacing lead at GeoForm
ring implantation. No valve-related reoperations were
required, although 1 patient with tricuspid valve endocardi-
tis was denied surgery because of end-stage cirrhosis. Of the
49 patients, 16 died during the follow-up period, with
8 from cardiac causes. Survival at 1, 3, and 5 years postop-
eratively was 87%, 81%, and 75%, respectively (Figure 1).
All patients had undergone early echocardiography
(either intraoperatively or within 6 months), revealing a
meanMR grade of 0.2 0.4 (range, 0-4þ) in the early post-
operative period. Of the 81 patients surviving the perioper-
ative period, 61 (75%) had undergone echocardiography
>6 months postoperatively. In these patients, at the last
follow-up point (mean, 41  18 months), the mean MR
grade was 0.7 0.7, with 2 patients developing2þ recur-
rent mitral insufficiency. The freedom from recurrentgery c November 2014
TABLE 1. Patient characteristics
Variable Value
Patients (n) 86
Age (y) 66  12
Male gender 51 (59)
EF (%) 31  11





NYHA class III-IV 71 (83)
Diabetes 18 (21)
COPD 9 (10)
Atrial fibrillation 11 (13)
Vascular disease 12 (14)
Urgent presentation 33 (38)
Previous MI 59 (68)
Data presented as mean  standard deviation or n (%), unless otherwise noted. EF,
Ejection fraction; MR, mitral regurgitation; NYHA, New York Heart Association;
COPD, chronic obstructive pulmonary disease; MI, myocardial infarction.
FIGURE 1. Kaplan-Meier curve summarizing actuarial patient survival.
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D2þMR at 5 years was 86% (Figure 2). Paired analysis of
the ejection fraction revealed a significant increase relative
to the preoperative measurements (39%  14% vs 33% 
12%; P ¼ .003). Significant LV remodeling was also
observed, with the LV end-diastolic diameter decreasing
from 6.0  0.8 cm to 5.4  0.9 cm (P ¼ .0002) and the
LV end-systolic diameter decreasing from 5.0  09 cm to
4.4  1.1 cm (P ¼ .0002). The peak and mean
diastolic mitral valve gradient was 12.0  4.5 and
4.6  1.9 mm Hg, respectively.
The quality of life data are summarized in Figure 3. No
significant differences were found between our patient
group and the general age-matched population for the
individual health measures of the SF-36 or the composite
mental or physical health score. When compared by
individual age group (45-54, 55-64, and>65 years), theTABLE 2. Operative data
Variable Value
Ring size
26 mm 60 (70)
28 mm 26 (30)
CABG 67 (78)
TV procedure 21 (24)
Reoperative surgery 17 (20)
Maze 11 (13)
IABP 10 (12)
LV lead/PPM 37 (43)
CPB time (min) 237  74
Crossclamp time (min) 190  64
Data presented as n (%) or mean  standard deviation. CABG, Coronary artery
bypass grafting; TV, tricuspid valve; IABP, intra-aortic balloon pump; PPM, perma-
nent pacemaker; CPB, cardiopulmonary bypass; LV, left ventricular.
The Journal of Thoracic and CarGeoForm patients in category of the role limitations due
to physical problems fared worse than the age-matched
controls (P¼ .03) in the 45- to 54-year age group. However,
significantly better scores were achieved than those for the
age-matched controls in bodily pain in the 45- to 54-year
age group, social function in the >64-year age group,
mental health in the 55- to 64-year age group, and
>64-year age group and composite score of mental health
in the 55- to 64-year and>64-year age groups (P< .05
for all).FIGURE 2. Kaplan-Meier curve representing freedom from moderate
(2þ) or greater mitral regurgitation (MR) during postoperative follow-up.
diovascular Surgery c Volume 148, Number 5 1953
FIGURE 3. Bar graph summarizing mean Medical Outcomes Study
36-item short-form health survey sores by category for GeoForm patients
(white bars) and age-matched US population norms (black bars). The 8
dimensions of health included were physical functioning (PF), role limita-
tions due to physical problems (RP), bodily pain (BP), general health
perception (GH), vitality (VT), social function (SF), role limitations due
to emotional problems (RE), andmental health (MH). The composite scales
for overall physical (PCS) and mental (MCS) health are also shown. No sig-
nificant difference in the mean scores was observed for any of these
categories.




IMR has continued to frustrate surgeons and cardiolo-
gists alike. The pathophysiology of IMR is complex,
involving both the valvular and the subvalvular apparatus.
The simple surgical ‘‘fix’’ of undersized ring annuloplasty
has begun to illustrate its shortcomings, with significant
recurrent mitral insufficiency even at short-term follow-
up.9 The GeoForm annuloplasty ring has been specifically
designed to address the annular and leaflet perturbations
associated with IMR and potentially to alter the subvalvular
geometry and improve the clinical results. In our clinical
series, we found this prosthesis to be associated with good
perioperative outcomes and distant survival 5 years
postoperatively. Implantation of the GeoForm ring in
patients with IMR yielded a very low rate of recurrent mitral
insufficiency and good functional status of the patients at
follow-up.
Etiology-specific annuloplasty rings have been devel-
oped to customize mitral annular remodeling according to
the particular pathophysiology of mitral insufficiency.
Currently, the IMR ETiologix ring, GeoForm ring (both
Edwards Lifesciences), and Rigid Saddle Annuloplasty
Ring (St Jude Medical, St Paul, Minn) are the annuloplasty
prostheses specifically available for clinical repair of IMR
and offering a variable degree of SL annular reduction.10
Dilatation of this annular dimension has been thought to
be central to the pathogenesis of IMR. In the present series,
the GeoForm ring performed well in a high-risk IMR
patient population with a low ejection fraction and
high EuroSCORE II score. These outcomes have been are
corroborated by a recent Italian series,11 with similar1954 The Journal of Thoracic and Cardiovascular Sursurvival (81%) and rate of recurrent moderate IMR at
3.5 years postoperatively. These investigators did not
observe significant transmitral pressure gradients either at
rest or during exercise,11 supporting our findings. Our study
did not include stress testing; however, 80% of our patients
at the last follow-up point were either in NYHA class I or II
and their subjective well-being, determined from the SF-36
scores, was equal to that of the age-matched general popu-
lation, making the possibility of clinical mitral stenosis less
likely. Significant LV remodeling was observed in our
study, with an increase in the LVejection fraction. However,
it would be difficult to ascertain whether the positive effect
of surgery on ventricular geometry and performance
resulted from annular remodeling or concurrent procedures,
because a large proportion of patients underwent
simultaneous coronary artery bypass grafting. A number
of patients had also undergone placement of a LV lead or
revision of a pacemaker at surgery for subsequent
biventricular pacing. This treatment modality alone can
reduce IMR and contribute to LV remodeling.12,13 Most
likely, the combination of these factors and prevention of
volume overload through durable control of mitral
insufficiency contributed to the observed effects on the
LV geometry.
It would be tempting to speculate that the SL annular
reduction achieved with implantation of the GeoForm ring
directly affected the subvalvular geometry, because isolated
SL reduction of 30% has been shown to abolish chronic
ovine IMR14 and reposition the posterior papillary
muscle.15 Undersized suture annuloplasty has also been
demonstrated to reduce the LV radius of curvature,6
demonstrating the effect of an annular intervention on the
subvalvular geometry. The SL diameter of a 26-mm and a
28-mm GeoForm ring is 17.1 mm and 18.2 mm,10
respectively, and, as such, the mean reduction in the SL
size in our patients was>50% and would be expected to
exert influence on the geometry of the subvalvular
apparatus. However, in experimental acute IMR, the
GeoForm ring has not been shown to offer a greater
reduction in the leaflet tenting area than prostheses with a
less radical SL design.16 Furthermore, such an extreme
reduction in the annular SL size could be deleterious to
systolic function of the myocardial segments adjacent to
the mitral annulus.17 Prospective studies of patients with
IMR and implanted with the GeoForm ring using serial
magnetic resonance imaging to precisely evaluate the
annular, subvalvular, and ventricular geometry are needed
to define the direct effect of this prosthesis on LV
remodeling.
The inherent shape of the GeoForm ring radically
changes the annular geometry from a D-shaped native
annulus to a rectangular shape. Clinical concerns have
been raised regarding extreme annular reduction and
increased stress that could lead to ring dehiscence. Thisgery c November 2014
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Dwas not observed in the present series; however, the follow-
up data are not complete and long-term data are yet not
available. However, the implantation technique was
standardized to include a high number of sutures (15-20)
and tying down of the posterior annular ‘‘hump’’ last.
Recent acute ovine studies have shown that ring
implantation will be associated with increased strain,
particularly in the lateral annulus, that is smallest for the
flexible annuloplasty bands.18 However, the strain
associated with the GeoForm ring was similar to that
observed with physiologically shaped prostheses such as
the Physio annuloplasty ring and the Rigid Saddle
Annuloplasty Ring (St Jude Medical). The investigators
concluded that the degree of annular SL reduction cannot
predict the annular strain profile of ring prosthesis.18
From these data, the likelihood of annular disruption with
the GeoForm ring might not be different from that of any
other rigid prosthesis. In addition, although the GeoForm
ring increased the anterior mitral leaflet strain in these
same experimental animal, this again did not differ from
that of other rigid annuloplasty rings19 as did not altered
anterior leaflet motion.20 The posterior leaflet motion,
however, was more restricted with implantation of the
GeoForm ring; therefore, it is feasible that the asymmetric
posterior leaflet tethering observed in some patients with
IMR could be exacerbated by implantation of this device.
De Bonis and colleagues11 identified asymmetric leaflet
tethering as a predictor of recurrent MR in their series of
patients with IMR treated with the GeoForm ring.
The GeoForm annuloplasty ring is a new tool in the
surgical armamentarium aimed at reliable and lasting
correction of IMR; however, the reported clinical
experience has been very limited. Randomized studies
have shown that ring annuloplasty and concurrent coronary
artery bypass grafting will be superior to coronary artery
bypass grafting alone in addressing even moderate degrees
of MR.21 As such, repairing IMR provides incremental
clinical benefit. However, clinical controversy still exists
regarding whether the repair will be superior to valve
replacement. A recent multicenter randomized trial of
mitral valve repair using standard undersized complete
ring annuloplasty versus mitral valve repair showed
equivalent outcomes at 1 year, with superior control of
mitral insufficiency seen with valve replacement.22 The
almost 30% recurrent MR rate at 1 year reported in that trial
was not observed in the present study. However, it is diffi-
cult to speculate whether the use of an etiology-specific
ring prosthesis would alter the findings of that important
trial. The findings from the present study support the use
of this prosthesis in high-risk patients with IMR, offering
durable control of mitral insufficiency and favorable
perioperative and distant survival. Additional studies are
needed to define the long-term outcomes of the GeoForm
ring and identify optimal candidates for its implantation.The Journal of Thoracic and CarStudy Limitations
Although our study has presented encouraging clinical
results with the use of the GeoForm ring, several limitations
must be recognized to interpret the data in the appropriate
context. The patient population was a heterogeneous group
of preoperative morbidities and operative procedures and,
as such, the isolated effect of GeoForm annuloplasty on
the clinical outcomes was difficult to ascertain. However,
the prosthesis provided very good control of IMR, with a
low rate of recurrent insufficiency at 5 years in a study pop-
ulation of high-risk patients with IMR and ischemic cardio-
myopathy. The echocardiographic and telephone follow-up
data were only 75% complete, and potential patients with
recurrent MR and/or distant morbidity might not have
been included in the analysis. Ours was a retrospective
study, and the postoperative imaging intervals were not
standardized to allow for longitudinal assessment of MR
and LV geometry. The patient criteria for implantation of
the GeoForm ring were not defined but left to the discretion
of the surgeon and, hence, surely introduced selection bias.References
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